Зофеноприл при лечении острого инфаркта миокарда

1. Mancia G. Blood pressure variability: mechanisms and clinical significance. J Cardiovasc Pharmacol 1990; 16: 1–6.
2. Pfeffer M, Pfeffer I. Reversing cardiac hypertrophy in hypertension. N Engl J Med 1990; 322: 1388–90.
3. Vakili B, Okin P, Devereux R. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334–41.
4. Недогода С.В., Сергеев В.С., Брель У.А. Зофеноприл при артериальной гипертензии – один из многих или не равный многим? Consilium Medicum 2005; 7: 893–96.
5. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999; 17: 115–33.
6. Tio R, de Langen C, de Graef P et al. The effects of oral pretreatment with zofenopril, an angiotensin converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drug ther 1990; 4: 695–704.
7. Преображенский Д.В., Сидоренко Б.А., Першуков И.В. и др. Ингибиторы ангиотензин-превращающего фермента в остром периоде инфаркта миокарда: место зофеноприла. Кардиология. 2006; 5: 99–105.
8. Ambrosioni Е, Borghi С, Маgnani В. Survival of mуосardiаl infarction long-term eva1uation (SМILE) study: rationale, design, organization, and outcome definitions. Control Сlin Trials 1994; 15 (3): 201–10.
9. Ambrosioni Е, Borghi С, Magnani В et аll. for the Surviva1 of Myocardial Infinctiоn Long-Тerm Eva1uation (SМILE) Study Investigators. The effect of the angiotensin-converting еnzymе inhibitor zofenopril оn mortality and morbidity after anterior myocanlia1 infarctiоn. New Engl J Med 1995; 332: 80–5.
10. Gruрро Italiano per lа Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together оn 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22.
11. ISIS Соllаbоrativе Group. ISIS-4: randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction. Ciroulation 1993; 88 (Suppl. 1): 1–394.
12. Borghi C, Bacchelli S, Degli Espositi D et al. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J 2006; 152: 470–7.
13. Borghi С, Ambrosioni Е, Мagnani В. Effects of the early administration of zofenopril оn onset and progression of congestive heart failure in patients with anterior wаll acute myocardial infarction. Тhе SМILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Cardiol 1996; 78 (3): 317–22.
14. Borghi C, Bacchelli S, Degli Espositi D et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute myocardial infarction in patients with arterial hypertension. Am J Hypertens 1999; 12: 665–72.
15. Borghi C, Bacchelli S, Degli Espositi D et al. Effects of the early ACE inhibiton in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabet Care 2003; 26: 1862–8.
16. Borghi C, Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction. Results of the Survival of Myocardial Infarction Long-Term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145: 80–7.

С.Н.Терещенко, И.В.Жиров

ГОУ ВПО МГМСУ Росздрава